• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

How to manage sodium-glucose cotransporter-2 inhibitors in the critically ill patient?

作者信息

Garcia Bruno, Ostermann Marlies, Legrand Matthieu

机构信息

Department of Intensive Care, Centre Hospitalier Universitaire de Lille, Lille, France.

Department of Intensive Care, King's College London, Guy's & St Thomas' Hospital, London, UK.

出版信息

Intensive Care Med. 2025 Jan;51(1):143-145. doi: 10.1007/s00134-024-07704-0. Epub 2024 Dec 2.

DOI:10.1007/s00134-024-07704-0
PMID:39621048
Abstract
摘要

相似文献

1
How to manage sodium-glucose cotransporter-2 inhibitors in the critically ill patient?如何在危重症患者中管理钠-葡萄糖协同转运蛋白2抑制剂？
Intensive Care Med. 2025 Jan;51(1):143-145. doi: 10.1007/s00134-024-07704-0. Epub 2024 Dec 2.
2
The effect of preoperative sodium-glucose cotransporter 2 inhibitors on the incidence of perioperative metabolic acidosis: A retrospective cohort study.术前钠-葡萄糖共转运蛋白 2 抑制剂对围手术期代谢性酸中毒发生率的影响：一项回顾性队列研究。
BMC Endocr Disord. 2022 Aug 20;22(1):209. doi: 10.1186/s12902-022-01126-z.
3
Potential of Sodium-Glucose Cotransporter-2 Inhibitors in the Management of Heart Failure With Preserved Ejection Fraction: A Narrative Review.钠-葡萄糖协同转运蛋白2抑制剂在射血分数保留的心力衰竭管理中的潜力：一项叙述性综述
Cureus. 2024 Nov 18;16(11):e73906. doi: 10.7759/cureus.73906. eCollection 2024 Nov.
4
Sodium-glucose cotransporter-2 inhibitor use in patients with a Fontan circulation.钠-葡萄糖协同转运蛋白2抑制剂在接受Fontan循环手术患者中的应用
Cardiol Young. 2025 Apr;35(4):745-747. doi: 10.1017/S1047951125000514. Epub 2025 Feb 26.
5
Management of sodium-glucose cotransporter 2 inhibitors during the perioperative period: A retrospective comparative study.围手术期钠-葡萄糖共转运蛋白 2 抑制剂的管理：一项回顾性对比研究。
J Perioper Pract. 2021 Oct;31(10):391-398. doi: 10.1177/1750458920948693. Epub 2020 Sep 8.
6
Obesity Treatments to Improve Type 1 Diabetes (OTID): a randomized controlled trial of the combination of glucagon-like peptide 1 analogues and sodium-glucose cotransporter 2 inhibitors-protocol for Obesity Treatments to Improve Type 1 Diabetes (the OTID trial).改善 1 型糖尿病的肥胖治疗（OTID）：胰高血糖素样肽 1 类似物和钠-葡萄糖共转运蛋白 2 抑制剂联合治疗的随机对照试验——改善 1 型糖尿病的肥胖治疗（OTID 试验）方案。
Trials. 2024 Feb 16;25(1):129. doi: 10.1186/s13063-024-07930-3.
7
Sodium-Glucose Cotransporter Inhibitors for the Treatment of Type 1 Diabetes Mellitus.钠-葡萄糖共转运蛋白抑制剂治疗 1 型糖尿病。
Clin Drug Investig. 2020 Nov;40(11):991-1000. doi: 10.1007/s40261-020-00949-9.
8
Investigating the place of sodium-glucose cotransporter-2 inhibitors and dual sodium-glucose cotransporter-1 and dual sodium-glucose cotransporter-2 inhibitors in heart failure therapy: a systematic review of the literature.探究钠-葡萄糖协同转运蛋白2抑制剂以及钠-葡萄糖协同转运蛋白1/钠-葡萄糖协同转运蛋白2双重抑制剂在心力衰竭治疗中的地位：文献系统综述
Heart Fail Rev. 2024 Mar;29(2):549-558. doi: 10.1007/s10741-024-10388-9. Epub 2024 Feb 1.
9
Narrative review investigating the nephroprotective mechanisms of sodium glucose cotransporter type 2 inhibitors in diabetic and nondiabetic patients with chronic kidney disease.综述探讨钠-葡萄糖共转运蛋白 2 抑制剂在糖尿病和非糖尿病慢性肾脏病患者中的肾保护机制。
Front Endocrinol (Lausanne). 2023 Dec 20;14:1281107. doi: 10.3389/fendo.2023.1281107. eCollection 2023.
10
Case report: Sodium-glucose cotransporter 2 inhibitors induce left ventricular reverse remodeling in anthracycline-related cardiac dysfunction-a case series.病例报告：钠-葡萄糖协同转运蛋白2抑制剂诱导蒽环类药物相关心脏功能障碍患者左心室逆向重构——病例系列
Front Cardiovasc Med. 2023 Aug 22;10:1250185. doi: 10.3389/fcvm.2023.1250185. eCollection 2023.

引用本文的文献

1
Euglycemic diabetic ketoacidosis associated with a sodium-glucose co transporter 2 inhibitor use in a trauma patient: a case report.与钠-葡萄糖协同转运蛋白2抑制剂使用相关的正常血糖性糖尿病酮症酸中毒在一名创伤患者中的病例报告
Int J Emerg Med. 2025 Aug 13;18(1):152. doi: 10.1186/s12245-025-00963-8.
2
Postoperative Outcomes Among Sodium-Glucose Cotransporter 2 Inhibitor Users.钠-葡萄糖协同转运蛋白2抑制剂使用者的术后结局
JAMA Surg. 2025 Apr 30. doi: 10.1001/jamasurg.2025.0940.
3
Understanding the disease: euglycemic ketoacidosis with SGLT2 inhibitors.

本文引用的文献

1
Dapagliflozin for Critically Ill Patients With Acute Organ Dysfunction: The DEFENDER Randomized Clinical Trial.达格列净治疗急性器官功能障碍危重症患者：DEFENDER 随机临床试验。
JAMA. 2024 Aug 6;332(5):401-411. doi: 10.1001/jama.2024.10510.
2
Blinded Withdrawal of Long-Term Randomized Treatment With Empagliflozin or Placebo in Patients With Heart Failure.心力衰竭患者长期随机接受恩格列净或安慰剂治疗后出现盲目停药。
Circulation. 2023 Sep 26;148(13):1011-1022. doi: 10.1161/CIRCULATIONAHA.123.065748. Epub 2023 Aug 24.
3
Critical Analysis of the Effects of SGLT2 Inhibitors on Renal Tubular Sodium, Water and Chloride Homeostasis and Their Role in Influencing Heart Failure Outcomes.
认识这种疾病：SGLT2抑制剂相关的正常血糖性酮症酸中毒。
Intensive Care Med. 2025 Apr;51(4):779-782. doi: 10.1007/s00134-025-07806-3. Epub 2025 Feb 3.
SGLT2 抑制剂对肾小管钠、水和氯稳态的影响及其影响心力衰竭结局的作用的批判性分析。
Circulation. 2023 Jul 25;148(4):354-372. doi: 10.1161/CIRCULATIONAHA.123.064346. Epub 2023 Jul 24.
4
Sodium glucose co-transporter-2 inhibitors in intensive care unit patients with type 2 diabetes: a pilot case control study.钠-葡萄糖共转运蛋白 2 抑制剂在 2 型糖尿病重症监护病房患者中的应用：一项初步的病例对照研究。
Crit Care. 2023 May 16;27(1):189. doi: 10.1186/s13054-023-04481-y.
5
Population-Level Implications of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Preserved Ejection Fraction in the US.美国钠-葡萄糖共转运蛋白 2 抑制剂对射血分数保留型心力衰竭的人群影响。
JAMA Cardiol. 2023 Jan 1;8(1):66-73. doi: 10.1001/jamacardio.2022.4348.
6
Effects of Early Empagliflozin Initiation on Diuresis and Kidney Function in Patients With Acute Decompensated Heart Failure (EMPAG-HF).恩格列净对急性失代偿性心力衰竭患者利尿和肾功能的影响（EMPAG-HF）。
Circulation. 2022 Jul 26;146(4):289-298. doi: 10.1161/CIRCULATIONAHA.122.059038. Epub 2022 Jun 29.
7
Gliflozins in the Management of Cardiovascular Disease.格列净类药物在心血管疾病管理中的应用
N Engl J Med. 2022 May 26;386(21):2024-2034. doi: 10.1056/NEJMra2115011.
8
Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF.达格列净起始治疗心力衰竭伴射血分数降低患者后估算肾小球滤过率的初始下降（降低）：来自 DAPA-HF 的观察。
Circulation. 2022 Aug 9;146(6):438-449. doi: 10.1161/CIRCULATIONAHA.121.058910. Epub 2022 Apr 20.
9
Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial.达格列净在伴有心血管代谢危险因素的 COVID-19 住院患者中的应用（DARE-19）：一项随机、双盲、安慰剂对照、3 期临床试验。
Lancet Diabetes Endocrinol. 2021 Sep;9(9):586-594. doi: 10.1016/S2213-8587(21)00180-7. Epub 2021 Jul 21.
10
Euglycemic Ketoacidosis as a Complication of SGLT2 Inhibitor Therapy.血糖正常的酮症酸中毒作为 SGLT2 抑制剂治疗的一种并发症。
Clin J Am Soc Nephrol. 2021 Aug;16(8):1284-1291. doi: 10.2215/CJN.17621120. Epub 2021 Feb 9.